Patent 11760801 was granted and assigned to Janssen Biotech on September, 2023 by the United States Patent and Trademark Office.
The disclosure provided herein relates to monospecific and multispecific antibodies, that bind CEACAM1 and optionally CEACAM5 and/or CEACAM6, and methods of producing and using the described antibodies.